Targeting CD26hi T-cells for Cancer Therapy
Inventors at MUSC have identified a unique human CD4+ T cell population that expresses high levels of surface CD26, termed CD26high T cells, which mediate durable antitumor immunity in vivo, and have immediate clinical relevance for designing new vaccines and cellular therapies.
CD26high T cells simultaneously secrete elevated IL-17A, IFN-? and IL-22 compared to Th1, Th2 or Th17 cells. When infused into mice bearing human tumors, CD26high T cells more efficiently reconstituted immunodeficient hosts and persisted long-term compared to other subsets. Remarkably, CD26high T cells engineered with a first generation CD3? mesothelin-specific chimeric antigen receptor (CAR) were capable of ablating large human mesothelioma tumors when infused into mice.
Spinal Implant System for Reduction & Internal Implant Stabilization of Human Spondylolisthesis Deformity
The Hercules spinal implant device and system is to be used for reduction and internal implant stabilization of human vertebral spondylolisthesis deformity. It is a standalone system with unique design that allows an anterior surgical approach to realign and simultaneously stabilize the spinal vertebral segments while protecting and preserve nerve function and not damaging other human body visceral anatomy in order to correct all grades of spondylolisthesis. The proposed solution is to use two implants in the interbody space, allowing greater flexibility to handle high grades of spondylolisthesis that utilize a locking mechanism when the spine has returned to proper alignment to provide the same stability as that of a single implant. Additionally, the reduction system used to realign the spine is designed to minimize the physical strain of the surgeon while realigning the spine, which could have high resistive forces in high grades of spondylolisthesis. This spinal reduction system is able to treat any grade of spondylolisthesis without supplemental fixation. This is used to treat patients with the spondylolisthesis deformity that causes extreme back or leg pain, and who have found no improvement with more conservative treatment options.
Titanium Clip Metal Detector to Aid Breast Surgery
This titanium metal detector localizes titanium biopsy clips placed at the site of breast tissue biopsies. The device is a handheld metal detector that can be inserted into a surgical incision to help locate small titanium markers without an invasive procedure to insert a localizing wire or radioactive seed. The device uses a two-step detection system which is initiated by running the scanning wand across the patient’s breast as a means of rapidly guiding clinicians to the marker’s general location. Once an approximate location is determined, the probing wand is used to identify the marker’s precise location. An incision is made and the probing wand guides the surgeon’s path to the marker through continuous feedback. The system relates proximity information to clinicians both through auditory feedback mechanisms and a digital display on the base.
Cooperative Therapeutic Effect of Immune Checkpoint Blockade & Anti-sMIC
The invention is a new immune-based therapy modality to treat MIC+ malignancies by the combination of a sMIC neutralizing antibody and an immune checkpoint agonist. This invention presents that a combination of sMIC antibody and anti-CTLA4 or anti-PD1/PD-L1 has superior therapeutic effect over monotherapy of individual reagents. This is a new therapeutic modality to improve the clinic response to anti-CTLA4 or anti-PD1/PD-L1 therapy.
FRD Medical Innovation Interest Group Meetup
MIG and the MUSC FRD will be hosting an Innovators Meetup on March
28th, 2017 at Halo to learn about what it means to be a physician inventor,
and the future of what the Medical Innovation Interest Group will be
offering to medical students at MUSC.
Dr. Nancy DeMore will be sharing her experience as a medical innovator,
and there will be plenty of time to share ideas after! Drink tickets and
food will be provided. Come hang out, discuss medical innovation, and
get involved in the future of medicine.
When: Tuesday, March 28th - 4:30 - 6 pm
Be Aware of the Ideas of March!
Win $1500 for your lab or Idea!
Its as easy as...
1) Submit your idea to FRD via Record of Invention (ROI)*
2) Include new Data or Proof of Principle: Get 2 chances
3) New Inventor: Get 2 chances
* Rules: Pending an initial review by FRD with each ROI resulting in one chance for the $1500 award, doubling of the chances at the discretion of FRD. If the invention comes from a faculty, staff, students, or employees without an affiliated lab, monies will be applied to invention’s advancement towards commercialization under the direction of FRD. All ROIs must be submitted to FRD between March 1st and by 5pm on Friday March 31st. Drawing to be held on April 1, 2017 and announced via the FRD web site. Any additional questions please email firstname.lastname@example.org.
National Academy of Inventors, MUSC recognize new fellow
Charleston, S.C. (Feb. 8, 2017)
–Craig Beeson, Ph.D., Medical University of South Carolina College of Pharmacy professor and metabolics core director, has been named a fellow of the National Academy of Inventors (NAI). Election to NAI fellows status is a high professional distinction accorded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society. The 2016 fellows will be inducted on April 6, 2017, as part of the Sixth Annual Conference of the National Academy of Inventors at the John F. Kennedy Presidential Library and Museum in Boston, MA.
Neuroene Therapeutics Awarded $225,000 STTR Research Grant
Startup rooted in MUSC investigators’ efforts to find new anti-seizure drugs
Charleston, S.C. (Aug. 24, 2016) – Neuroene Therapeutics, a startup company born from unique research by two Medical University of South Carolina (MUSC) investigators, secured a Small Business Technology Transfer (STTR) grant for $225,000 in July from the National Institute of Neurological Disorders and Stroke (NINDS).
Neuroene Therapeutics is using the Phase I STTR grant to help further develop a novel class of compounds for treating epilepsy. In the U.S. alone, epilepsy’s estimated direct and indirect costs total $15.5 billion, according to the Health and Medicine Division of the National Academies of Sciences.
FRD Welcomes Two New Board Members
The MUSC Foundation for Research Development (FRD) welcomes two new board members. These two new members exemplify innovation and development and will be a great asset to the Foundation. Welcome!
Dr. Robert D. McQuade
Ph.D. | Biochemistry, UNC
Currently Executive Vice President and Chief Strategic Officer at Otsuka Pharmaceuticals Development and Commercialization.
Dr. Paul Williamson
M.D | University of Massachusetts
SCTR Technology Development Grant Awardees
Congratulations to Nathan Dolloff, Ph.D. and James Chou, Ph.D. on receiving the most recent SCTR technology development grants.
James Chou, Ph.D.'s research focus is centered around the neuro-vitamin K (VK) synthase UBIAD1, which has recently been identified through a forward genetic screen as a dominant enhancer of the Parkinson’s disease (PD) establishing an additional link among mitochondria, vitamin K, and PD pathogenesis. Supplementation of VK reverses the non-flight phenotype observed in the drosophila model. Unfortunately, for humans, neuronal VK requires a series of metabolic processes and direct synthesis by UBIAD1 in the central nervous system in situ, and cannot be supplemented through dietary means. We have developed VK analogs that can easily penetrate blood-brain barrier and showed effective in the chemical induced PD model. The SCTR-FRD Grant will allow the optimization of the lead drug candidate’s dosing routine instead of performing the costly efficacy experiments blindly. With the funded study, it will also significantly move the project forward for future efficacy studies.
MUSC Start-Up Wins Prestigious National Award
Congratulations to ToleRaM Nanotech, LLC for winning a National TechConnect Innovation Award, which is meant to recognize innovative technology that has the potential to make a difference in a special sector, such as medicine. Only 15% of submitted entries receive the prestigious award.
Click here for more information.